# Glenmark Pharmaceuticals (GLENMARK) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/glenmark

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹2,590
- Change: +4.36%
- As of: 2026-11-06
- 1D return: +4.36%
- 5D return: +12.67%
- 1M return: +18.15%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

Glenmark Pharmaceuticals (₹2,590) is exhibiting strong daily momentum on 2026-11-06, marked by an extreme volume-price anomaly with a 7.98x volume ratio and a +4.4% close gain. The stock is trading near its 20-day and 50-day range highs (+84.1%) and at the upper end of its 252-day range (+89.5%). Daily trend indicators are bullish: price sits above all key moving averages (EMA/SMA 20/50/200) and the Supertrend, supported by an established ADX of 31.32. However, this short-term strength contrasts with a bearish monthly Supertrend despite high monthly ADM conviction (ADX 57.72), suggesting the current rally may be testing longer-term resistance. Immediate upside faces resistance at ₹2,615.67 (+0.99%), while downside support lies at ₹2,578.93 (-0.43%) and ₹2,530.37 (-2.30%). Volatility remains elevated (ATR 3.47%, annualized vol 30.8%). A sustained break above ₹2,615.67 with continued volume would confirm further daily upside, whereas a failure to hold above ₹2,578.93 could signal a pullback toward the ₹2,530 pivot.

- Extreme daily participation: Volume was 7.98x normal on 2026-11-06 with a +4.4% price gain, signaling strong institutional or large-cap interest.
- Trend divergence: Daily structure is bullish (price above all MAs and Supertrend; ADX 31.32), but monthly Supertrend remains bearish, indicating potential overhead supply.
- Critical levels: Resistance at ₹2,615.67 (+0.99%); immediate support at ₹2,578.93 (-0.43%); secondary support at ₹2,530.37 (-2.30%).
- Range position: Trading in the top 16% of its 20-day and 50-day ranges, and top 10% of its 252-day range, limiting near-term upside cushion.

- Hammer
- Bullish Engulfing Reversal

### News Context

Glenmark Pharmaceuticals reported Q2 FY27 results on November 6, 2026, showing a 56.8% year-on-year decline in profit and a nearly 30% drop in revenue to ₹4,247.3 crore. The company clarified that its core North American business grew approximately 31% when excluding deferred out-licensing income, while India formulations expanded by around 14%. US sales of $126.6 million exceeded analyst estimates of $105 million but remained significantly lower than prior-year figures. Despite the earnings contraction, Glenmark maintained its full-year FY27 revenue guidance of Rs 17,000-18,000 crore and Ebitda margin target of 21-22%. Shares fell approximately 4% following the announcement.

- Q2 FY27 profit plunged 56.8% YoY and revenue dropped ~30% to ₹4,247.3 crore, driven by sharp declines in North American profitability.
- Core North American business grew ~31% ex-deferred out-licensing income; India formulations grew ~14%; US sales of $126.6m beat estimates of $105m.
- Company maintained full-year FY27 revenue guidance of Rs 17,000-18,000 crore and Ebitda margin target of 21-22%.
- Shares declined ~4% post-results amid broader market focus on Q2 earnings releases.

- [Glenmark Pharma shares fall 4% after Q2 profit plunges 57%, revenue drops 30%](https://www.businesstoday.in/markets/stocks/story/glenmark-pharma-shares-fall-4-after-q2-profit-plunges-57-revenue-drops-30-566092-2026-11-06)
- [GIFT Nifty down 123 pts; Airtel, ONGC, Titan, Hindalco, Britannia among top stock in focus](https://www.businesstoday.in/markets/stocks/story/gift-nifty-down-123-pts-airtel-ongc-titan-hindalco-britannia-among-top-stock-in-focus-566080-2026-11-06)
- [Top stocks to watch today: Hindalco, Bharti Airtel, LIC, ONGC shares in focus on Friday, 6 Nov | Full list](https://www.livemint.com/market/stock-market-news/top-stocks-to-watch-today-hindalco-bharti-airtel-lic-ongc-shares-in-focus-on-friday-6-nov-full-list-11793928004864.html)
- [Glenmark Pharma shares will react to better-than-expected US sales in Q2, 14% growth in India biz](https://www.cnbctv18.com/market/glenmark-pharma-share-price-reaction-better-than-expected-us-sales-q2-india-business-20028468.htm)
- [Stocks in news: Bharti Airtel, LIC, Titan, ONGC, Bharti Hexacom, Glenmark Pharma and Astral](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-bharti-airtel-lic-titan-ongc-bharti-hexacom-glenmark-pharma-and-astral/articleshow/135584151.cms)

### What Changed

Glenmark Pharmaceuticals reported Q2 FY2026-27 results on November 5, 2026, showing consolidated revenue of ₹4,247.3 million and adjusted PAT of ₹4,852 million. While the company highlighted strong like-for-like growth of approximately 20% in revenue and 31% in core North American business (excluding deferred out-licensing income), reported headline profit fell 56.8% year-on-year due to a US$15.28 million settlement with Humana Inc. for antitrust litigation. The stock price rose to ₹2,590.0 on November 6 from ₹2,481.8 previously, despite market headlines noting a 4% intraday fall following initial profit decline reports. Management maintained full-year FY27 guidance of ₹17,000–18,000 crore revenue and 21–22% EBITDA margin.

- Q2 FY2026-27 Consolidated Revenue: ₹4,247.3 million (+20% like-for-like YoY); Adjusted PAT: ₹4,852 million (11.4% margin).
- Profit Decline Driver: Reported PAT fell 56.8% YoY due to a one-time exceptional item of ₹2,838.75 million (US$15.28M Humana settlement), which does not admit liability.
- Regional Performance: India formulations grew ~14%; North America core business grew ~31% (ex-deferred out-licensing); EU grew 6.2%; Emerging Markets grew 33.2%.
- Market Reaction & Guidance: Share price observed at ₹2,590.0 on Nov 6 (up from ₹2,481.8); Company reaffirmed FY27 revenue guidance of ₹17,000–18,000 crore and EBITDA margin target of 21–22%.

- [Glenmark Pharma shares fall 4% after Q2 profit plunges 57%, revenue drops 30%](https://www.businesstoday.in/markets/stocks/story/glenmark-pharma-shares-fall-4-after-q2-profit-plunges-57-revenue-drops-30-566092-2026-11-06)
- [GIFT Nifty down 123 pts; Airtel, ONGC, Titan, Hindalco, Britannia among top stock in focus](https://www.businesstoday.in/markets/stocks/story/gift-nifty-down-123-pts-airtel-ongc-titan-hindalco-britannia-among-top-stock-in-focus-566080-2026-11-06)
- [Top stocks to watch today: Hindalco, Bharti Airtel, LIC, ONGC shares in focus on Friday, 6 Nov | Full list](https://www.livemint.com/market/stock-market-news/top-stocks-to-watch-today-hindalco-bharti-airtel-lic-ongc-shares-in-focus-on-friday-6-nov-full-list-11793928004864.html)
- [Glenmark Pharma shares will react to better-than-expected US sales in Q2, 14% growth in India biz](https://www.cnbctv18.com/market/glenmark-pharma-share-price-reaction-better-than-expected-us-sales-q2-india-business-20028468.htm)
- [Stocks in news: Bharti Airtel, LIC, Titan, ONGC, Bharti Hexacom, Glenmark Pharma and Astral](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-bharti-airtel-lic-titan-ongc-bharti-hexacom-glenmark-pharma-and-astral/articleshow/135584151.cms)
- [Audio recording of Q2 FY 2026-27 Earnings Call held on November 06, 2026 |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GLENMARK_06112026122317_BSE_NSE_EarningsCall_Signed.pdf)
- [Glenmark Pharmaceuticals Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1853_WebXMLFile_20261106_133728213.xml)
- [Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/GLENMARK_05112026170258_SEInitmationresults.pdf)
- [Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 05, 2026, titled "Press Release for Q2 FY'27". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/GLENMARK_05112026171553_PR_MDA_05112026.pdf)
- [Glenmark Pharmaceuticals Limited has informed the Exchange regarding 'Investors Presentation'. |SUBJECT: Updates](https://nsearchives.nseindia.com/corporate/GLENMARK_05112026172410_SEInvestorPresentation.pdf)

### Official Filings

Glenmark Pharmaceuticals reported consolidated revenue of Rs. 42,473 million for Q2 FY 2026-27, reflecting approximately 20% like-for-like year-over-year growth. Adjusted Profit After Tax (PAT) was Rs. 4,852 million with an EBITDA margin of 20.3%. The half-year results included an exceptional item of Rs. 2,838.75 million, primarily driven by a US$15 million settlement with Humana, Inc., related to U.S. antitrust litigation; the company clarified this settlement does not involve an admission of liability. Regional performance showed strong momentum in North America (~31% core growth) and Emerging Markets (33.2%), while India grew ~14%. Commercially, the company launched RYALTRIS® in Brazil and WINLEVI® in several EU markets, and secured regulatory approvals for Trastuzumab RezeteCan in Australia. Additionally, Ichnos Glenmark Innovation (IGI) will present updated clinical data for ISB 2001 at the ASH Annual Meeting in December 2026.

- Q2 FY 2026-27 Consolidated Revenue: Rs. 42,473 million, up ~20% year-over-year on a like-for-like basis.
- Profitability Metrics: Adjusted PAT of Rs. 4,852 million (margin 11.4%) and EBITDA of Rs. 8,638 million (margin 20.3%).
- Legal Settlement: Half-year results include an exceptional item of Rs. 2,838.75 million, comprising a US$15 million settlement with Humana, Inc. regarding U.S. antitrust litigation, without admission of liability.
- Pipeline & Commercial Updates: Launches of RYALTRIS® (Brazil) and WINLEVI® (EU); regulatory approval for Trastuzumab RezeteCan (Australia); IGI to present ISB 2001 data at ASH 2026.

- [Audio recording of Q2 FY 2026-27 Earnings Call held on November 06, 2026 |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GLENMARK_06112026122317_BSE_NSE_EarningsCall_Signed.pdf)
- [Glenmark Pharmaceuticals Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1853_WebXMLFile_20261106_133728213.xml)
- [Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/GLENMARK_05112026170258_SEInitmationresults.pdf)
- [Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 05, 2026, titled "Press Release for Q2 FY'27". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/GLENMARK_05112026171553_PR_MDA_05112026.pdf)
- [Glenmark Pharmaceuticals Limited has informed the Exchange regarding 'Investors Presentation'. |SUBJECT: Updates](https://nsearchives.nseindia.com/corporate/GLENMARK_05112026172410_SEInvestorPresentation.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1754088_05112026073445_WEB.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1754080_05112026073159_WEB.xml)
- [Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 04, 2026, titled "Ichnos Glenmark Innovation (IGI) to Present Updated Clinical Data for ISB 2001 (ABBV 2001) in Relapsed/Refractory Multiple Myeloma at 68th ASH Annual Meeting". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/GLENMARK_04112026193501_SEPressRelease04112026.pdf)
- [GLENMARK PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1853_WebXMLFile_20261023_114324786.xml)
- [Financial Results |Meeting Date: 05-Nov-2026](https://nsearchives.nseindia.com/corporate/GLENMARK_23102026113823_SE_Intimation_BM.pdf)

### Fundamentals

Glenmark Pharmaceuticals demonstrates a significant acceleration in top-line growth, with TTM sales rising to ₹17,737 crore and YoY sales growth reaching 76% for the Sep 2025 quarter. This expansion is accompanied by robust profitability improvements; TTM net profit surged to ₹1,798 crore, and ROCE improved sharply to 40% as of Mar 2026. However, earnings quality faces scrutiny due to a sharp sequential decline in Q2 FY2026-27, where net profit fell from ₹483 crore to ₹264 crore despite revenue growth. Cash flow dynamics have also shifted, with CFO swinging from negative territory in prior years to ₹3,445 crore in Mar 2026, though cash reserves decreased to ₹1,290 crore by Sep 2026. Working capital efficiency has deteriorated, with debtor days increasing to 107 days.

- TTM sales grew to ₹17,737 crore with 76% YoY growth in the Sep 2025 quarter, while TTM net profit reached ₹1,798 crore.
- Q2 FY2026-27 net profit declined sequentially to ₹264 crore from ₹483 crore in Q1, signaling margin or expense pressure.
- ROCE improved significantly to 40% (Mar 2026), but working capital metrics weakened, with debtor days rising to 107 days.
- Cash reserves dropped to ₹1,290 crore as of Sep 2026, down from ₹2,647 crore a year earlier, despite strong Mar 2026 CFO.

### Bull Case

Glenmark Pharmaceuticals presents a conditional upside case anchored in operational resilience and technical momentum, despite reported headline profit declines. The company’s core North American business grew approximately 31% when excluding deferred out-licensing income, demonstrating underlying commercial strength. Additionally, the India formulation business achieved like-for-like growth of around 14%, providing a stable domestic counterweight to US volatility. Financially, Glenmark maintained its full-year FY27 revenue guidance of ₹17,000–18,000 crore and an EBITDA margin target of 21–22%, signaling management confidence in future performance. Technically, the stock exhibits bullish signals on both daily and weekly timeframes as of November 6, 2026, with the Supertrend indicating upward momentum and significant period returns, including a +43.1% gain over the last year. This constructive interpretation holds provided that US sales execution remains robust and the company meets its stated margin targets.

- Core North American business grew ~31% excluding deferred out-licensing income, highlighting underlying operational strength despite headline profit drops.
- India formulation business posted like-for-like growth of ~14%, offering diversified revenue support.
- Company maintained full-year FY27 revenue guidance of ₹17,000–18,000 crore and EBITDA margin target of 21–22%.
- Technical indicators show bullish daily and weekly Supertrend directions, with a 1-year return of +43.1%.

- [Glenmark Pharma shares fall 4% after Q2 profit plunges 57%, revenue drops 30%](https://www.businesstoday.in/markets/stocks/story/glenmark-pharma-shares-fall-4-after-q2-profit-plunges-57-revenue-drops-30-566092-2026-11-06)
- [GIFT Nifty down 123 pts; Airtel, ONGC, Titan, Hindalco, Britannia among top stock in focus](https://www.businesstoday.in/markets/stocks/story/gift-nifty-down-123-pts-airtel-ongc-titan-hindalco-britannia-among-top-stock-in-focus-566080-2026-11-06)
- [Top stocks to watch today: Hindalco, Bharti Airtel, LIC, ONGC shares in focus on Friday, 6 Nov | Full list](https://www.livemint.com/market/stock-market-news/top-stocks-to-watch-today-hindalco-bharti-airtel-lic-ongc-shares-in-focus-on-friday-6-nov-full-list-11793928004864.html)
- [Glenmark Pharma shares will react to better-than-expected US sales in Q2, 14% growth in India biz](https://www.cnbctv18.com/market/glenmark-pharma-share-price-reaction-better-than-expected-us-sales-q2-india-business-20028468.htm)
- [Stocks in news: Bharti Airtel, LIC, Titan, ONGC, Bharti Hexacom, Glenmark Pharma and Astral](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-bharti-airtel-lic-titan-ongc-bharti-hexacom-glenmark-pharma-and-astral/articleshow/135584151.cms)
- [Audio recording of Q2 FY 2026-27 Earnings Call held on November 06, 2026 |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GLENMARK_06112026122317_BSE_NSE_EarningsCall_Signed.pdf)
- [Glenmark Pharmaceuticals Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1853_WebXMLFile_20261106_133728213.xml)
- [Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/GLENMARK_05112026170258_SEInitmationresults.pdf)
- [Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 05, 2026, titled "Press Release for Q2 FY'27". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/GLENMARK_05112026171553_PR_MDA_05112026.pdf)
- [Glenmark Pharmaceuticals Limited has informed the Exchange regarding 'Investors Presentation'. |SUBJECT: Updates](https://nsearchives.nseindia.com/corporate/GLENMARK_05112026172410_SEInvestorPresentation.pdf)

### Bear Case

Glenmark Pharmaceuticals reported a sharp deterioration in Q2 FY27 profitability, with net profit plunging 56.8% year-on-year and revenue declining nearly 30% to ₹4,247.3 crore. This contraction was primarily driven by steep drops in North American earnings, although the company clarified that core US business grew approximately 31% when excluding deferred out-licensing income. Despite these headline declines, management maintained its full-year FY27 revenue guidance of ₹17,000–18,000 crore and EBITDA margin target of 21–22%. The market reacted negatively, with shares falling approximately 4% on November 6, 2026, closing at ₹2,590. While technical indicators show a bullish daily supertrend and strong recent returns (YTD +27.8%, 1-year +43.1%), the monthly trend remains bearish, and the stock has experienced a maximum drawdown of -22.1% over the measured period.

- Q2 FY27 net profit fell 56.8% YoY and revenue dropped ~30% to ₹4,247.3 crore, driven by North American earnings contraction.
- Shares declined ~4% to close at ₹2,590 on November 6, 2026, following the earnings release.
- Monthly technical trend is bearish despite a bullish daily supertrend; maximum drawdown stands at -22.1%.
- Management retained full-year FY27 revenue guidance of ₹17,000–18,000 crore and EBITDA margin target of 21–22%.

- [Glenmark Pharma shares fall 4% after Q2 profit plunges 57%, revenue drops 30%](https://www.businesstoday.in/markets/stocks/story/glenmark-pharma-shares-fall-4-after-q2-profit-plunges-57-revenue-drops-30-566092-2026-11-06)
- [GIFT Nifty down 123 pts; Airtel, ONGC, Titan, Hindalco, Britannia among top stock in focus](https://www.businesstoday.in/markets/stocks/story/gift-nifty-down-123-pts-airtel-ongc-titan-hindalco-britannia-among-top-stock-in-focus-566080-2026-11-06)
- [Top stocks to watch today: Hindalco, Bharti Airtel, LIC, ONGC shares in focus on Friday, 6 Nov | Full list](https://www.livemint.com/market/stock-market-news/top-stocks-to-watch-today-hindalco-bharti-airtel-lic-ongc-shares-in-focus-on-friday-6-nov-full-list-11793928004864.html)
- [Glenmark Pharma shares will react to better-than-expected US sales in Q2, 14% growth in India biz](https://www.cnbctv18.com/market/glenmark-pharma-share-price-reaction-better-than-expected-us-sales-q2-india-business-20028468.htm)
- [Stocks in news: Bharti Airtel, LIC, Titan, ONGC, Bharti Hexacom, Glenmark Pharma and Astral](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-bharti-airtel-lic-titan-ongc-bharti-hexacom-glenmark-pharma-and-astral/articleshow/135584151.cms)
- [Audio recording of Q2 FY 2026-27 Earnings Call held on November 06, 2026 |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GLENMARK_06112026122317_BSE_NSE_EarningsCall_Signed.pdf)
- [Glenmark Pharmaceuticals Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1853_WebXMLFile_20261106_133728213.xml)
- [Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/GLENMARK_05112026170258_SEInitmationresults.pdf)
- [Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 05, 2026, titled "Press Release for Q2 FY'27". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/GLENMARK_05112026171553_PR_MDA_05112026.pdf)
- [Glenmark Pharmaceuticals Limited has informed the Exchange regarding 'Investors Presentation'. |SUBJECT: Updates](https://nsearchives.nseindia.com/corporate/GLENMARK_05112026172410_SEInvestorPresentation.pdf)

### FAQs

**Why did Glenmark's reported profit fall 57% despite revenue growth?**

The 56.8% year-on-year decline in Q2 FY27 Profit After Tax (PAT) was driven by a Rs 2,838.75 million exceptional item: a US$15 million settlement with Humana Inc. for antitrust litigation costs. Excluding this one-time charge, adjusted PAT was Rs 4,852 million (margin 11.4%). The company also clarified that its core North American business actually grew ~31% when excluding deferred out-licensing income.

**What is the current market price and key technical level to watch?**

As of November 6, 2026, shares closed at ₹2,590.00 after opening lower at ₹2,365.50. The stock faces immediate resistance at ₹2,615.67 (0.99% above). Support levels are noted at ₹2,578.93 and ₹2,530.37. While daily and weekly trends show bullish signals, the monthly trend remains bearish, indicating mixed momentum across timeframes.

**How does Glenmark's regional performance compare between India and the US?**

In Q2 FY27, India formulations showed like-for-like growth of ~14%. In contrast, US sales were $126.6 million, significantly lower than the prior year but exceeding analyst estimates of $105 million. Overall consolidated revenue was ₹4,247.3 crore, with Emerging Markets posting strong growth of 33.2% and the EU growing 6.2%.

**Has management revised its full-year financial guidance?**

No. Despite the quarterly earnings contraction, Glenmark maintained its full-year FY27 revenue guidance of ₹17,000–18,000 crore and an EBITDA margin target of 21–22%. This guidance stands as a forward-looking estimate against the reported half-year consolidated revenue of ₹1,43,126.91 million.

- [Glenmark Pharma shares fall 4% after Q2 profit plunges 57%, revenue drops 30%](https://www.businesstoday.in/markets/stocks/story/glenmark-pharma-shares-fall-4-after-q2-profit-plunges-57-revenue-drops-30-566092-2026-11-06)
- [GIFT Nifty down 123 pts; Airtel, ONGC, Titan, Hindalco, Britannia among top stock in focus](https://www.businesstoday.in/markets/stocks/story/gift-nifty-down-123-pts-airtel-ongc-titan-hindalco-britannia-among-top-stock-in-focus-566080-2026-11-06)
- [Top stocks to watch today: Hindalco, Bharti Airtel, LIC, ONGC shares in focus on Friday, 6 Nov | Full list](https://www.livemint.com/market/stock-market-news/top-stocks-to-watch-today-hindalco-bharti-airtel-lic-ongc-shares-in-focus-on-friday-6-nov-full-list-11793928004864.html)
- [Glenmark Pharma shares will react to better-than-expected US sales in Q2, 14% growth in India biz](https://www.cnbctv18.com/market/glenmark-pharma-share-price-reaction-better-than-expected-us-sales-q2-india-business-20028468.htm)
- [Stocks in news: Bharti Airtel, LIC, Titan, ONGC, Bharti Hexacom, Glenmark Pharma and Astral](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-bharti-airtel-lic-titan-ongc-bharti-hexacom-glenmark-pharma-and-astral/articleshow/135584151.cms)
- [Audio recording of Q2 FY 2026-27 Earnings Call held on November 06, 2026 |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/GLENMARK_06112026122317_BSE_NSE_EarningsCall_Signed.pdf)
- [Glenmark Pharmaceuticals Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1853_WebXMLFile_20261106_133728213.xml)
- [Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/GLENMARK_05112026170258_SEInitmationresults.pdf)
- [Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 05, 2026, titled "Press Release for Q2 FY'27". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/GLENMARK_05112026171553_PR_MDA_05112026.pdf)
- [Glenmark Pharmaceuticals Limited has informed the Exchange regarding 'Investors Presentation'. |SUBJECT: Updates](https://nsearchives.nseindia.com/corporate/GLENMARK_05112026172410_SEInvestorPresentation.pdf)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Uptrend
- Weekly trend: Weak Uptrend
- Pivot point: ₹2,493.63
- Risk regime: Price Risk Requires Attention

### Support levels
- 2204.8
- 2115.1
- 2019.6865234375

### Resistance levels
- 2615.666666666667

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +4.36% |
| return_10 | +19.54% |
| return_1m | +12.07% |
| return_1y | +43.06% |
| return_20 | +18.15% |
| return_3m | +14.10% |
| return_5 | +12.67% |
| return_6m | +8.93% |
| return_since_start | +60.42% |
| return_ytd | +27.83% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -22.11% |
| annualized_volatility | +30.82% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Glenmark Pharmaceuticals Limited Q2 FY2026-27: Revenue up, profit down

Revenue from operations rose 3.4% sequentially to ₹4,157 crore in Q2 FY2026-27, but fell 31.3% year on year. Profit for the period declined 45.4% from Q1 to ₹264 crore, with a ₹284 crore exceptional charge contributing to the sequential drop; operating cash flow was negative ₹203 crore.

## Revenue growth trails expense growth

Revenue from operations increased from ₹4,018 crore in Q1 FY2026-27 to ₹4,157 crore in Q2, following ₹3,771 crore in Q4 FY2025-26. Compared with Q2 FY2025-26, revenue was down 31.3% from ₹6,047 crore. Total income rose 4.1% sequentially to ₹4,250 crore, including ₹93 crore of other income.

Total expenses increased 5.4% sequentially to ₹3,628 crore, faster than total income. Major expense items included other expenses of ₹1,050 crore, employee benefits of ₹1,028 crore, materials consumed of ₹838 crore, purchases of stock in trade of ₹530 crore and depreciation and amortisation of ₹180 crore. Profit before exceptional items and tax consequently edged down 3.3% from Q1 to ₹622 crore.

## Exceptional charge weighs on reported profit

A ₹284 crore exceptional charge, against none in Q1, reduced profit before tax to ₹338 crore, down 47.4% sequentially. Finance costs increased 18.1% to ₹63.8 crore from ₹54.0 crore in Q1, while tax expense fell to ₹74.5 crore from ₹160.6 crore.

Profit for the period was ₹264 crore, down 45.4% from ₹483 crore in Q1 and 56.8% from ₹610 crore in Q2 FY2025-26. Basic earnings per share fell to ₹9.35 from ₹17.11 in Q1. Trailing 12-month EPS was ₹51.43.

## Cash flow and working-capital balances

Cash flow from operating activities was negative ₹203 crore in Q2, while investing activities used ₹326 crore. Free cash flow was negative ₹530 crore, and financing activities provided an inflow of ₹602 crore.

At 30 September 2026, trade receivables were ₹5,494 crore and inventories were ₹3,746 crore, compared with ₹4,963 crore and ₹3,431 crore, respectively, at 31 March 2026. Current borrowings stood at ₹867 crore, versus nil at the March year-end. Cash and cash equivalents were ₹1,290 crore at quarter-end, up from ₹1,175 crore at 31 March 2026.

## Comprehensive income

Comprehensive income was ₹231 crore in Q2, down from ₹523 crore in Q1. Other comprehensive income was negative ₹32 crore, compared with positive ₹40 crore in the prior quarter.

## Key Takeaway

Sequential revenue growth did not translate into higher pre-exceptional profit: expenses rose faster than income, and a ₹284 crore exceptional charge drove much of the decline in reported earnings. The year-on-year declines in revenue and profit, negative operating cash flow, and higher receivables and inventory balances are the key changes for investors to track.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q1
- As of: 2026-06-30
- Promoter holding: +46.65%
- FII holding: +20.89%
- DII holding: +18.60%
- Mutual fund holding: +16.76%
- Retail holding: +7.91%
- Promoter pledged: +0.00%

### Major reported shareholders

- SALDANHA FAMILY TRUST — +45.44% (Trusts)
- HDFC MUTUAL FUND - HDFC MID-CAP FUND — +6.22%
- GOVERNMENT PENSION FUND GLOBAL — +3.89%
- AMANSA HOLDINGS PRIVATE LIMITED — +2.22%
- INVESCO INDIA CONTRA FUND — +2.20%
- BANDHAN NIFTY 200 MOMENTUM 30 INDEX FUND — +1.28%
- UTI MULTI CAP FUND — +1.15%
- BLANCHE ELIZABETH SALDANHA — +0.39%
- GLENN MARIO SALDANHA — +0.36%
- CHERYLANN MARIA PINTO — +0.27%

## Official filings

- 2026-11-06 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_06112026122317_BSE_NSE_EarningsCall_Signed.pdf)
- 2026-11-06 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1853_WebXMLFile_20261106_133728213.xml)
- 2026-11-05 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_05112026170258_SEInitmationresults.pdf)
- 2026-11-05 — Press Release: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_05112026171553_PR_MDA_05112026.pdf)
- 2026-11-05 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_05112026172410_SEInvestorPresentation.pdf)
- 2026-11-05 — Financial Results Filing: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1754088_05112026073445_WEB.xml)
- 2026-11-05 — Financial Results Filing: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1754080_05112026073159_WEB.xml)
- 2026-11-04 — Press Release: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_04112026193501_SEPressRelease04112026.pdf)
- 2026-10-23 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1853_WebXMLFile_20261023_114324786.xml)
- 2026-10-23 — Board Meeting Notice: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_23102026113823_SE_Intimation_BM.pdf)
- 2026-10-23 — Board Meeting Notice: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1853_WebXMLFile_20261023_114324786.xml)
- 2026-10-23 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1853_WebXMLFile_20261023_170609050.xml)
- 2026-10-23 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_23102026171432_Intimation_Earnings_Call_Signed.pdf)
- 2026-10-19 — Shareholding Disclosure: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1741223_19102026122950_WEB.xml)
- 2026-10-06 — Press Release: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_06102026083500_SEIntimation_06102026.pdf)
- 2026-09-28 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_28092026181622_TWC_CoveringLetter_signed.pdf)
- 2026-09-28 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_1853_WebXMLFile_20260928_181810334.xml)
- 2026-09-23 — Press Release: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_23092026083959_SEPressRelease23092026.pdf)
- 2026-09-21 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_21092026145007_SE_Investor_Meet.pdf)
- 2026-09-21 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1853_WebXMLFile_20260921_150451651.xml)
- 2026-09-11 — Credit Rating Update: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_11092026084352_BSE_NSE_IndiaRatings_Signed.pdf)
- 2026-09-11 — Press Release: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_11092026085036_Press_Release_11092026_Signed.pdf)
- 2026-09-11 — Generic Announcement: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_11092026185249_AGMOutcome.pdf)
- 2026-09-11 — Regulatory Filing: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/RESULT_VOTING_1723766_11092026065545_WEB.xml)
- 2026-08-21 — Press Release: Glenmark Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLENMARK_21082026084736_Press_Release_21082026_Signed.pdf)

## News and market events

- 2026-11-06 — BUSINESSTODAY: **Glenmark Pharma shares fall 4% after Q2 profit plunges 57%, revenue drops 30%** — Glenmark Pharmaceuticals shares fell approximately 4% after the company reported a 56.8% year-on-year decline in second-quarter profit and a nearly 30% drop in revenue, driven largely by a steep decrease in North American earnings. The company clarified that its core North American business actually grew around 31% when excluding deferred out-licensing income, while India formulations and emerging markets also posted growth. Despite the reported earnings contraction, Glenmark maintained its full-year FY27 revenue guidance of Rs 17,000-18,000 crore and Ebitda margin target of 21-22%, citing res — [Source](https://www.businesstoday.in/markets/stocks/story/glenmark-pharma-shares-fall-4-after-q2-profit-plunges-57-revenue-drops-30-566092-2026-11-06)
- 2026-11-06 — BUSINESSTODAY: **GIFT Nifty down 123 pts; Airtel, ONGC, Titan, Hindalco, Britannia among top stock in focus** — Multiple Indian listed companies including Oil & Natural Gas Corporation, Bharti Airtel, Titan Company, Glenmark Pharmaceuticals, Britannia Industries, Kalpataru Projects International, Godfrey Phillips India, KNR Constructions, Lemon Tree Hotels, and Ashoka Buildcon reported quarterly financial results or received significant corporate orders on November 06, 2026. Concurrently, GIFT Nifty futures indicated a weak market opening due to negative global cues. — [Source](https://www.businesstoday.in/markets/stocks/story/gift-nifty-down-123-pts-airtel-ongc-titan-hindalco-britannia-among-top-stock-in-focus-566080-2026-11-06)
- 2026-11-06 — Mint: **Top stocks to watch today: Hindalco, Bharti Airtel, LIC, ONGC shares in focus on Friday, 6 Nov | Full list** — The Indian stock market is expected to open lower on November 6, with GIFT Nifty signaling a weak start despite the previous session's sharp rally. Several major stocks including Hindalco, Bharti Airtel, LIC, ONGC, Titan, Glenmark Pharma, and Vedant Fashions are in focus due to Q2 FY27 earnings releases and corporate developments. — [Source](https://www.livemint.com/market/stock-market-news/top-stocks-to-watch-today-hindalco-bharti-airtel-lic-ongc-shares-in-focus-on-friday-6-nov-full-list-11793928004864.html)
- 2026-11-06 — CNBC-TV18: **Glenmark Pharma shares will react to better-than-expected US sales in Q2, 14% growth in India biz** — Glenmark Pharmaceuticals reported Q2FY27 revenue of ₹4,247.3 crore, exceeding analyst estimates despite a 29.8% year-on-year decline driven by sharp drops in North American sales and profitability. The company's India formulation business showed like-for-like growth of around 14%, while US sales of $126.6 million surpassed the estimated $105 million, though they were significantly lower than the prior year's figures. — [Source](https://www.cnbctv18.com/market/glenmark-pharma-share-price-reaction-better-than-expected-us-sales-q2-india-business-20028468.htm)
- 2026-11-06 — Economic Times: **Stocks in news: Bharti Airtel, LIC, Titan, ONGC, Bharti Hexacom, Glenmark Pharma and Astral** — Indian equity markets extended their winning streak to a sixth consecutive session, with the Nifty 50 gaining 576 points as investors tracked September-quarter earnings from key companies. Bharti Airtel, LIC, Titan Company, and ONGC reported substantial year-on-year increases in consolidated net profit, while Glenmark Pharmaceuticals faced a significant decline in net profit and revenue. These corporate developments are influencing investor sentiment amid the broader market rally. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-bharti-airtel-lic-titan-ongc-bharti-hexacom-glenmark-pharma-and-astral/articleshow/135584151.cms)
- 2026-11-05 — CNBC-TV18: **Top 10@10 | D-Street soars, Wall Street cheers Democrat sweep, Ronaldo retires** — Indian equities extended their winning streak to a sixth session, with the Sensex and Nifty rising on improving sentiment, falling crude oil prices, and expectations of broader market recovery. US midterm election results reshaped sectoral outlooks by creating winners and losers linked to political themes, while domestic Q2 earnings highlighted strong performances from Bharti Airtel and Titan alongside profit declines at other firms. — [Source](https://www.cnbctv18.com/business/top-1010-d-street-soars-wall-street-cheers-democrat-sweep-ronaldo-retires-20028356.htm)
- 2026-11-05 — FREEPRESSJOURNAL.IN: **Glenmark Pharmaceuticals Q2 Profit Plunges 56.7% To ₹264 Crore** — Glenmark Pharmaceuticals reported a 56.7% year-on-year decline in consolidated net profit to ₹264 crore for Q2 FY27, alongside a 29.8% drop in revenue and a sharp contraction in EBITDA margins to 20%. Despite these headline declines, the company stated its underlying business remains resilient and on track for FY27 guidance, citing strong growth in India formulations and core North American operations. The firm also highlighted ongoing progress in its oncology pipeline, including data presentations and expected product launches. — [Source](https://www.freepressjournal.in/business/glenmark-pharmaceuticals-q2-profit-plunges-567-to-264-crore)
- 2026-11-05 — IANSLIVE.IN: **Glenmark Pharma's Q2 profit plunges 57 pc to Rs 264 crore; revenue drops 30 pc** — Glenmark Pharmaceuticals reported a 56.7% year-on-year decline in consolidated net profit to Rs 264 crore and a 29.8% drop in revenue to Rs 4,247.3 crore for Q2 FY27, driven by sharp contractions in EBITDA margins. Despite these headline declines, the company stated its underlying business remains resilient and on track for FY27 guidance, citing strong growth in India formulations, North America, and emerging markets. The stock closed 0.65% lower at Rs 2,485.50 on the BSE following the earnings announcement. — [Source](https://ianslive.in/glenmark-pharmas-q2-profit-plunges-57-pc-to-rs-264-crore-revenue-drops-30-pc--20261105185640)
- 2026-10-11 — BUSINESSTODAY: **Indian pharma leaders seek faster trials, state-backed market for new drugs** — Indian pharmaceutical industry, innovative medicines India, clinical trials India, pharma regulatory challenges, Sun Pharma Organon acquisition, Glenmark AbbVie deal, pharma R&D investment, Indian pharma global expansion, IFQM Symposium 2026, pharma market access India — [Source](https://www.businesstoday.in/industry/pharma/story/indian-pharma-leaders-seek-faster-trials-state-backed-market-for-new-drugs-560883-2026-10-11)
- 2026-10-05 — Economic Times: **Indian companies must invest in R&D, move from generics to innovation-led industry: Pharma leaders** — Indian pharmaceutical leaders emphasize the need for investment in innovation to transition from generics to innovative products. They highlight the importance of regulatory reforms and a strong ecosystem for research and development. Industry executives mention that the next decade will be critical for this transformation and urge companies to capitalize on scientific talent. Government initiatives are acknowledged as supportive in this endeavor for global competitiveness. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indian-pharma-industry-urged-to-shift-from-generics-to-innovation-led-growth-key-insights-from-industry-leaders/articleshow/134704527.cms)
- 2026-10-05 — CNBC-TV18: **Glenmark expects innovative drugs to drive higher revenue share: CMD Glenn Saldanha** — Glenmark Pharmaceuticals expects innovative drugs to contribute a higher share of revenue as it shifts focus beyond generics, CMD Glenn Saldanha said. — [Source](https://www.cnbctv18.com/market/glenmark-pharma-share-price-higher-revenue-innovative-drugs-chairman-md-glenn-saldanha-abbvie-deal-20004566.htm)
- 2026-09-23 — MONEYCONTROL: **Glenmark Pharma gets US FDA EIR for Goa plant; inspection closed with VAI status** — Glenmark Pharma, Glenmark Pharmaceuticals, Glenmark Pharma US FDA, Glenmark Goa plant, US FDA EIR, Glenmark VAI status, Glenmark FDA inspection, Goa manufacturing facility, US FDA inspection, Glenmark Pharma news — [Source](https://www.moneycontrol.com/news/business/glenmark-pharma-gets-us-fda-eir-for-goa-plant-inspection-closed-with-vai-status-14036106.html)
- 2026-09-23 — BUSINESSTODAY: **Glenmark Pharma stock reacts as Goa facility gets VAI status post USFDA inspection** — Glenmark Pharmaceuticals, Glenmark shares, Glenmark stock, US FDA, Glenmark Goa facility, FDA inspection, Establishment Inspection Report, EIR, VAI classification, Voluntary Action Indicated, Glenmark FDA update, pharmaceutical stocks, pharma news — [Source](https://www.businesstoday.in/markets/trending-stocks/story/glenmark-pharma-stock-reacts-as-goa-facility-gets-vai-status-post-usfda-inspection-557182-2026-09-23)
- 2026-09-23 — BUSINESS: **Glenmark receives EIR report for formulations facility in Goa** — The inspection was conducted at the Company's manufacturing facility from 22 June 2026 to 30 June 2026. — [Source](https://www.business-standard.com/markets/capital-market-news/glenmark-receives-eir-report-for-formulations-facility-in-goa-126092300179_1.html)
- 2026-09-22 — Mint: **Top stocks to buy in F&O segment: Glenmark, Bharat Forge, Varun Beverages by Jay Thakkar - Check short-term targets** — On September 22, domestic indices fell as IT stocks declined, overshadowing oil price drops. Nifty 50 dropped 0.36% to 23,329; Sensex fell 0.44% to 74,529. Technical levels suggest a trading range of 23,000-24,000, with potential positive momentum if a US-Iran deal is confirmed. — [Source](https://www.livemint.com/market/stock-market-news/top-stocks-to-buy-in-f-o-segment-glenmark-bharat-forge-varun-beverages-by-jay-thakkar-check-short-term-targets-11790077901117.html)
- 2026-09-16 — Mint: **Domestic pharma market sustains growth momentum, but margins remain key** — Domestic pharma growth remained strong in August, led by price hikes and new launches, but weak volumes and US tariff uncertainty mean a sustained margin recovery will be crucial for sector performance. — [Source](https://www.livemint.com/market/mark-to-market/indian-pharma-market-ipm-pharma-stocks-domestic-pharma-dr-reddy-s-laboratories-sun-pharma-ajanta-pharma-glenmark-11789538290089.html)
- 2026-09-11 — The Hindu: **Glenmark launches allergic rhinitis nasal spray RYALTRIS in Brazil** — Glenmark launches RYALTRIS nasal spray in Brazil, offering a dual-action treatment for allergic rhinitis after ANVISA approval. — [Source](https://www.thehindubusinessline.com/companies/glenmark-launches-allergic-rhinitis-nasal-spray-ryaltris-in-brazil/article71454792.ece)
- 2026-09-11 — BUSINESS: **Glenmark launches RYALTRIS Nasal Spray in Brazil** — Glenmark Specialty S.A., a wholly owned subsidiary of Glenmark Pharmaceuticals (Glenmark), today announced the launch of RYALTRIS Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis (AR) in adults and adolescents of 12 years of age and older. — [Source](https://www.business-standard.com/markets/capital-market-news/glenmark-launches-ryaltris-nasal-spray-in-brazil-126091100150_1.html)
- 2026-09-11 — The Hindu: **Stock Market Today Highlights, Sept 11: Sensex down 120 pts, Nifty closes at 23,398, logs 5th weekly loss as oil fears grip markets** — Sensex Today, Nifty 50 | Stock Market Highlights - Find here all the highlights related to Sensex, Nifty, BSE, NSE, share prices and Indian stock markets for 11 September 2026 — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-highlights-11th-september-2026/article71453005.ece)
- 2026-09-03 — Times of India: **Top stocks to buy today: Stock recommendations for September 3, 2026 - check list** — India Business News: Top stock market recommendations: Bank of Maharashtra, Glenmark Pharma, and Tata Technologies have been shared as the top stocks to buy today on Septe. — [Source](https://timesofindia.indiatimes.com/business/india-business/top-stock-recommendations-for-september-03-2026-bank-of-maharashtra-glenmark-pharma-tata-technologies-best-stocks-to-buy-today/articleshow/133723261.cms)
- 2026-08-21 — BUSINESS: **Nifty above 24,200 level; realty shares in demand** — At 12:30 IST, the barometer index, the S&P BSE Sensex gained 48.27 points or 0.06% to 77,585.99. The Nifty 50 index jumped 13.45 points or 0.05% to 24,244.55. — [Source](https://www.business-standard.com/markets/capital-market-news/nifty-above-24-200-level-realty-shares-in-demand-126082100525_1.html)
- 2026-08-21 — MONEYCONTROL: **Trade Spotlight: How should you trade Sai Life Sciences, EID Parry, Raymond, Glenmark Pharma, MCX India, and others on August 21?** — Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,Sai Life Sciences,Shriram Finance,EID Parry (India),Raymond,Glenmark Pharmaceuticals,Multi Commodity Exchange of India, — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-sai-life-sciences-eid-parry-raymond-glenmark-pharma-mcx-india-and-others-on-august-21-14011993.html)
- 2026-08-20 — BUSINESS: **Nifty breaks losing streak, Sensex rallies 628 points; sugar stocks shine** — Key equity benchmarks staged a strong rebound on Thursday, with the Nifty snapping a seven-session losing streak and reclaiming the 24,200 level, while the Sensex jumped over 600 points. The recovery was supported by easing US Treasury yields after the US Treasury announced plans to double its buybacks of longer-duration government debt, helping steady global bond markets and improve risk appetite. Buying was broad-based, led by IT, financials, realty and media stocks, while the broader market also ended higher. The rupee snapped its three-day losing streak and closed at 95.71 per dollar. Technically, the Nifty faces an immediate hurdle at 24,290-24,320, while 24,130-24,100 remains a crucial support zone. — [Source](https://www.business-standard.com/markets/capital-market-news/nifty-breaks-losing-streak-sensex-rallies-628-points-sugar-stocks-shine-126082000932_1.html)
- 2026-08-20 — MONEYCONTROL: **Taking Stock: Nifty snaps 7-day losing streak, reclaims 24,200, Sensex jumps 628 pts** — Taking Stock,Sensex,Nifty,Local markets — [Source](https://www.moneycontrol.com/news/business/markets/taking-stock-nifty-snaps-7-day-losing-streak-reclaims-24-200-sensex-jumps-628-pts-14011339.html)
- 2026-08-20 — MONEYCONTROL: **Buzzing Stocks: United Spirits gains after FSSAI revokes order; Glenmark rises on USFDA approval** — Buzzing Stocks — [Source](https://www.moneycontrol.com/news/business/markets/buzzing-stocks-united-spirits-gains-after-fssai-revokes-order-glenmark-rises-on-usfda-approval-14010862.html)

## Business profile

**Strategic vision:** Global pharmaceutical company advancing science-led therapies.

### Business segments
- **Oncology:** Glenmark's Oncology portfolio concentrates on advancing therapies for solid tumors and hematological malignancies, leveraging deep disease understanding and global collaborations.
- **Respiratory:** In the Respiratory segment, Glenmark addresses chronic conditions like asthma, COPD, and common ailments, offering advanced devices and therapies.
- **Dermatology:** Dermatology is a foundational and strategically important therapeutic area with over four decades of research and more than 120 products.

### Competitive strengths
- Decades of research in dermatology
- Expertise in biologics discovery and early development within oncology
- Established portfolio of over 120 dermatological products

## Related stocks

- [Abbott India Limited (Healthcare)](https://faxioms.com/stocks/abbotindia) — -0.85%
- [Ajanta Pharma Limited (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +0.55%
- [Alkem Laboratories Limited (Healthcare)](https://faxioms.com/stocks/alkem) — +2.06%
- [Aurobindo Pharma Limited (Healthcare)](https://faxioms.com/stocks/auropharma) — +0.84%
- [Biocon Limited (Healthcare)](https://faxioms.com/stocks/biocon) — +0.86%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/glenmark
Markdown representation: https://faxioms.com/stocks/glenmark?render=md